During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting inventory of Zepbound and Mounjaro ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... injectable obesity drug Zepbound and diabetes medicine ...

After years of preparation, Eli Lilly is on the brink of launching ... The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

News weighs on stocks of companies offering alternatives and some smaller ones developing their own drugs The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

1 Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency ... to meet demand for Lilly's latest diabetes and obesity treatments.

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year over year to $3.1 billion. Sales for Zepbound, which ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Eli Lilly is dialing back its 2024 forecast ... Company shares slipped in trading after the announcement. Sales of Lilly's diabetes treatment Mounjaro and weight loss counterpart Zepbound were ...